Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nightt… Read more
Vanda Pharmaceuticals Inc (VNDA) - Net Assets
Latest net assets as of December 2025: $327.19 Million USD
Based on the latest financial reports, Vanda Pharmaceuticals Inc (VNDA) has net assets worth $327.19 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($488.95 Million) and total liabilities ($161.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $327.19 Million |
| % of Total Assets | 66.92% |
| Annual Growth Rate | 15.48% |
| 5-Year Change | -35.2% |
| 10-Year Change | 149.13% |
| Growth Volatility | 105.41 |
Vanda Pharmaceuticals Inc - Net Assets Trend (2004–2025)
This chart illustrates how Vanda Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vanda Pharmaceuticals Inc (2004–2025)
The table below shows the annual net assets of Vanda Pharmaceuticals Inc from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $327.19 Million | -39.25% |
| 2024-12-31 | $538.55 Million | -1.17% |
| 2023-12-31 | $544.91 Million | +3.36% |
| 2022-12-31 | $527.20 Million | +4.41% |
| 2021-12-31 | $504.93 Million | +11.40% |
| 2020-12-31 | $453.27 Million | +10.30% |
| 2019-12-31 | $410.94 Million | +49.21% |
| 2018-12-31 | $275.42 Million | +109.63% |
| 2017-12-31 | $131.39 Million | +0.04% |
| 2016-12-31 | $131.33 Million | -1.28% |
| 2015-12-31 | $133.03 Million | -17.28% |
| 2014-12-31 | $160.82 Million | +264.47% |
| 2013-12-31 | $44.12 Million | +345.47% |
| 2012-12-31 | $9.90 Million | -70.41% |
| 2011-12-31 | $33.47 Million | -11.28% |
| 2010-12-31 | $37.73 Million | +63.82% |
| 2009-12-31 | $23.03 Million | -49.95% |
| 2008-12-31 | $46.02 Million | -45.04% |
| 2007-12-31 | $83.73 Million | +212.92% |
| 2006-12-31 | $26.76 Million | -12.74% |
| 2005-12-31 | $30.66 Million | +92.33% |
| 2004-12-31 | $15.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vanda Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38232089300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $59.00K | 0.02% |
| Other Comprehensive Income | $629.00K | 0.19% |
| Other Components | $721.26 Million | 220.44% |
| Total Equity | $327.19 Million | 100.00% |
Vanda Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Vanda Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT Berkah Beton Sadaya Tbk
OTCQX:BHBSY
|
$360.00 Million |
|
Potbelly Co
NASDAQ:PBPB
|
$360.01 Million |
|
Regenxbio Inc
NASDAQ:RGNX
|
$360.15 Million |
|
Hwaxin Environmental Co. Ltd. A
SHE:301265
|
$360.26 Million |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
$359.94 Million |
|
Hunan Baili Engineering Sci
SHG:603959
|
$359.90 Million |
|
Der International Home Furnishing Co Ltd
SHE:002631
|
$359.59 Million |
|
Timbercreek Financial Corp
PINK:TBCRF
|
$359.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vanda Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 538,546,000 to 327,186,000, a change of -211,360,000 (-39.2%).
- Net loss of 220,474,000 reduced equity.
- Other comprehensive income increased equity by 555,000.
- Other factors increased equity by 8,559,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-220.47 Million | -67.38% |
| Other Comprehensive Income | $555.00K | +0.17% |
| Other Changes | $8.56 Million | +2.62% |
| Total Change | $- | -39.25% |
Book Value vs Market Value Analysis
This analysis compares Vanda Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.55x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 253.50x to 1.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $0.03 | $8.60 | x |
| 2005-12-31 | $0.07 | $8.60 | x |
| 2006-12-31 | $1.67 | $8.60 | x |
| 2007-12-31 | $3.18 | $8.60 | x |
| 2008-12-31 | $1.73 | $8.60 | x |
| 2009-12-31 | $0.85 | $8.60 | x |
| 2010-12-31 | $1.32 | $8.60 | x |
| 2011-12-31 | $1.19 | $8.60 | x |
| 2012-12-31 | $0.35 | $8.60 | x |
| 2013-12-31 | $1.45 | $8.60 | x |
| 2014-12-31 | $4.38 | $8.60 | x |
| 2015-12-31 | $3.15 | $8.60 | x |
| 2016-12-31 | $3.02 | $8.60 | x |
| 2017-12-31 | $2.94 | $8.60 | x |
| 2018-12-31 | $5.19 | $8.60 | x |
| 2019-12-31 | $7.49 | $8.60 | x |
| 2020-12-31 | $8.21 | $8.60 | x |
| 2021-12-31 | $8.87 | $8.60 | x |
| 2022-12-31 | $9.25 | $8.60 | x |
| 2023-12-31 | $9.47 | $8.60 | x |
| 2024-12-31 | $9.26 | $8.60 | x |
| 2025-12-31 | $5.55 | $8.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vanda Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -102.02%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.49x
- Recent ROE (-67.38%) is below the historical average (-51.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -59.42% | -27881.95% | 0.00x | 1.11x | $-11.07 Million |
| 2005 | -77.89% | 0.00% | 0.00x | 1.17x | $-26.95 Million |
| 2006 | -237.36% | 0.00% | 0.00x | 1.36x | $-66.19 Million |
| 2007 | -88.46% | 0.00% | 0.00x | 1.16x | $-82.44 Million |
| 2008 | -110.96% | 0.00% | 0.00x | 1.09x | $-55.67 Million |
| 2009 | -155.70% | -788.50% | 0.02x | 9.80x | $-38.16 Million |
| 2010 | 19.06% | 20.42% | 0.17x | 5.65x | $3.42 Million |
| 2011 | -29.28% | -31.35% | 0.17x | 5.46x | $-13.15 Million |
| 2012 | -279.29% | -84.53% | 0.24x | 13.67x | $-28.65 Million |
| 2013 | -45.90% | -59.79% | 0.24x | 3.25x | $-24.67 Million |
| 2014 | 12.55% | 40.25% | 0.29x | 1.07x | $4.10 Million |
| 2015 | -29.97% | -36.27% | 0.52x | 1.60x | $-53.17 Million |
| 2016 | -13.71% | -12.33% | 0.69x | 1.60x | $-31.14 Million |
| 2017 | -11.85% | -9.43% | 0.80x | 1.56x | $-28.71 Million |
| 2018 | 9.15% | 13.05% | 0.58x | 1.21x | $-2.33 Million |
| 2019 | 28.12% | 50.86% | 0.47x | 1.18x | $74.46 Million |
| 2020 | 5.15% | 9.40% | 0.47x | 1.18x | $-21.99 Million |
| 2021 | 6.57% | 12.34% | 0.45x | 1.18x | $-17.34 Million |
| 2022 | 1.19% | 2.47% | 0.40x | 1.20x | $-46.44 Million |
| 2023 | 0.46% | 1.30% | 0.30x | 1.19x | $-51.98 Million |
| 2024 | -3.51% | -9.51% | 0.30x | 1.22x | $-72.75 Million |
| 2025 | -67.38% | -102.02% | 0.44x | 1.49x | $-253.19 Million |
Industry Comparison
This section compares Vanda Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc (VNDA) | $327.19 Million | -59.42% | 0.49x | $359.97 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |